JoseAFigueroaMD

PubMed

• 11 citations
  The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma.
  Christopher A. Schutt, Leonardo Mirandola, Jose A. Figueroa, Diane D. Nguyen, Joehassin Cordero
  Oncotarget. 2017-10-31
• 16 citations
  Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.
  Leonardo Mirandola, Elisa Pedretti, Jose A. Figueroa, Raffaella Chiaramonte, Michela Colombo
  Oncotarget. 2017-08-10
• 37 citations
  Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2
  Michael Dean, Joseph Boland, Meredith Yeager, Kate M. Im, Lisa Garland
  Gigascience. 2015-11-04

Journal Articles

• Novel Antigens in Non-small Cell Lung Cancer: SP17, AKAP4, and PTTG1 Are Potential Immunotherapeutic Targets  
  Mirandola L, Figueroa JA, Phan T, et al., Oncotarget, 1/1/2015
• Galectin-3 Inhibition Suppresses Drug Resistance, Motility, Invasion and Angiogenic Potential in Ovarian Cancer  
  Mirandola L, Yu Y, Cannon MJ, Jenkins MR, Rahman RL, Nguyen DD, Grizzi F, Cobos E, Figueroa JA, Chiriva-Internati M, Gynecologic Oncology
• Chimeric Antigen Receptor Engineering: A Right Step in the Evolution of Adoptive Cellular Immunotherapy  
  Figueroa JA, Reidy A, Mirandola L, Trotter K, Suvorava N, Figueroa A, Konala V, Aulakh A, Littlefield L, Grizzi F, Rahman R, Jenkins M, Musgrove B, Radhi S, D'Cunha N,..., Int Rev Immuno, 1/1/2015
• Cancer-Testis Antigens and Immunotherapy in the Light of Cancer Complexity  
  Grizzi F, Mirandola L, Qehajaj D, Cobos E, Figueroa JA, and Chiriva-Internati M, Int Rev Immuno, 1/1/2015
• Sex-Driven Differences in Immunological Responses: Challenges and Opportunities for the Immunotherapies of the Third Millennium  
  Mirandola L, Wade R, Verma R, Pena C, Hosiriluck S, Figueroa JA, Cobos E, Jenkins M, and Chiriva-Internati M, Int Rev Immunol, 1/1/2015
• Targeting Tumor Initiating Cells through Inhibition of Cancer Testis Antigens and Notch Signaling: A Hypothesis  
  Colombo M , Mirandola L, Reidy A, Suvorava N, Konala V, Chiaramonte R, Grizzi F, Rahman RL, Jenkins M, Nugyen D, Dalhbeck S, Cobos E, Figueroa JA, and Chiriva-Internati M, Int Rev Immunol, 1/1/2015
• The Role of Human Papilloma Virus (HPV) Infection in Non Anogenital Cancer and Promise of Immunotherapy: A Review  
  Cobos C, Figueroa JA, Mirandola, Colombo M, Sumer G, Figueroa A, Aulakh, Konola V, Verma R, Riaz J, Wade R, Sadeeh C, Pandey A, Radhi S, Nugyen DD, Jenkins M, Chiriva-..., Int Rev Immuno, 1/1/2014
• Galectins in cancer: carcinogenesis, diagnosis and therapy  
  Ebrahim AH, Alalawi Z, Mirandola L, Rakhshanda, Dahlbeck S, Nguyen D, Jenkins M, Grizzi F, Cobos E, Figueroa JA and Chiriva-Internati, Ann Trans Medicine, 1/1/2014
• Squamous Cell Carcinoma of the Sigmoid Colon Presenting with Severe Hypercalcemia  
  Ngo N, Edriss H, Figueroa JA, Nugent K, Clin Colorectal Cancer, 1/1/2014
• Galectins in Cancer: Carcinogenesis, Diagnosis and Therapy  
  Ebrahim AH, Alalawi Z, Mirandola L, Rakhshanda, Dahlbeck S, Nguyen D, Jenkins M, Grizzi F, Cobos E, Figueroa JA and Chiriva-Internati, Ann Trans Med, 1/1/2014
• Galectins as Therapeutic Targets for Hematological Malignancies: A Hopeful Sweetness  
  Pena C, Mirandola L, Figueroa JA, Hosiriluck N, Suvorava N, Trotter K, Reidy A, Rakhshanda R, Payne D, Jenkins M, Grizzi F, Littlefield L, Chiriva-Internati M, Cobos E, Ann Trans Medicine, 1/1/2014
• Anti-Galectin-3 Therapy: A New Chance for Multiple Myeloma and Ovarian Cancer?  
  Mirandola L, Yuefei Y, Cobos E, Figueroa JA, Jenkins M, Chiriva-Internati M, Int Rev Immuno, 1/1/2014
• Sperm Protein 17 is as Oncofetal Antigens: a Lesson from a Murine Model  
  Arnaboldi F, Menon A, Menegola E, Di Renzo F, Mirandola L, Grizzi F, Figueroa JA, Jenkins M, Barajon I, Chiriva-Internati M, Int Rev Immuno, 1/1/2014
• AAV2/8-hSMAD3 Gene Delivery Attenuates Aortic Atherogenesis, Enhances Th2 Response without Fibrosis, in LDLR-KO Mice on High Cholesterol Diet  
  Zhu H, Cao M, Figueroa JA, Cobos E, Uretsky BF, Chiriva-Internati M, Hermonat PL, J Transl Med, 1/1/2014
• Comparison of Efficacy of the Disease -specific LOX-1 and Constitutive Cytomegalovirus-promoters in Expressing Interlukin 10 through Adeno-associated Virus 2/8 Deliver...  
  Zhu H, Cao M, Mirandola L, Figueroa JA, Cobos E, Chiriva-Internati M,Hermonat PL, PLos ONE, 1/1/2014
• Translational Medicine, Biomarker Discovery and Tumor Complexity  
  Chiriva-Internati M, Cobos E, Figueroa JA, Grizzi F, Translational Medicine, 1/1/2013
• Notch-directed Microenvironment Reprogramming in Myeloma: A Single Path to Multiple Outcomes  
  Colombo M, Mirandola L, Platonova N, Apicella L, Basile A, Figueroa JA, Cobos E, Chiriva-Internati M and Chiaramonte R, Leukemia, 1/1/2013
• Historia De Tres Raptos  
  1/1/2011
• Improved Survival with Ipilimumab in Patients with Metastatic Melanoma  
  Hold S, O'Day S, McDermott D, et al., NEJM, 1/1/2010
• Ojos Verdes  
  Narrativas, 1/1/2010
• Amante Solitario  
  Concurso de Poesia: Vientos del Pasado, 1/1/2007
• Esperanza Futura  
  XXX Certamen Literario: Latinoamerica Escribe 2006, XXX Certamen Literario: Latinoamerica Escribe 2006, 1/1/2007
• Mujer Nocturna  
  XXX Certamen Literario: Latinoamerica Escribe 2006, XXX Certamen Literario: Latinoamerica Escribe 2006, 1/1/2007
• Mariposa  
  XXX Certamen Literario: Latinoamerica Escribe 2006, XXX Certamen Literario: Latinoamerica Escribe 2006, 1/1/2007
• Apologia  
  XXX Certamen Literario: Latinoamerica Escribe 2006, XXX Certamen Literario: Latinoamerica Escribe 2006, 1/1/2007
• Join now to see all

Books/Book Chapters

• Therapeutic Monoclonal Antibodies and Their Targets 
  Figueroa JA, Pena C, Mirandola L, et al.2015
• Cancer Immunology 
  Chapter: Immunopathology of Specific Cancers in Males and Females and Immunotherapy of Prostate and Cervical Cancer. 
  Page 401 - 412Chiriva-Internati, Maurizio, Fabio Grizzi, Gianluigi Taverna, Leonardo Mirandola, Scott W. Dahlbeck, Marjorie R. Jenkins, Diane D. Nguyen, Martin J. D’Souza, Everardo ...Springer, Berlin, Heidelberg2015
• Anisotropico, Poemas 
  Trafford Publishing Company2007
• Laboratory Medicine: The Selection and Interpretation of Clinical Laboratory Studies 
  Chapter: Reproductive System: Breast Cancer 
  Figueroa, J.A.; Yee, D.; McGuire, W.L.Editors: DA Noe, RC Rock.William and WilkinsEdition 824.,1994
• Laboratory Medicine: The Selection and Interpretation of Clinical Laboratory Studies. 
  Chapter: Reproductive System: Breast Cancer. 
  Page 824 - 827Figueroa, J.A.; Yee, D.; McGuire, W.L.Editors: DA Noe, RC Rock.William and Wilkins1994
• Join now to see all

Abstracts/Posters

• SP17 as a new immunotherapy target and biomarker for triple negative breast cancer.
  Chiriva-Internati M, Mirandola L, Cobos E, dahlbeck S, Nguyen D, Figueroa JA, Rahman RL, Immunology, 1/1/2015
• High-dose-rate brachytherapy as monotherapy for favorable-risk adenocarcinoma of the prostate delivered in a single 19 Gy fraction: Preliminary results of a prospectiv...
  Dahlbeck, Scott, Chase C. Hansen, A. Robert Kagan, Carlos Torres, Maurizio Chiriva-Internati, Everardo Cobos, Jose A. Figueroa, Diane Nguyen, Lukman Tijani, and Jaden ..., Cancer Research, 1/1/2015
• Cancer Testes Antigens: Potential New targets for Lung Cancer.
  Leonardo Mirandola, Jehanzeb Riaz, Rashmi Verma, Saba Radhi, Teresia Pham, Amardeep Aulakh, Venu Konala, Yuefei Yu, Fred Hardwick, Lukman Aderoju Tijani, Nicholas C. D..., J Clin Oncol, 1/1/2014
• Effect of the novel galectin-3 blocker, Gal3M, on the efficacy and reduction of toxicity of proteasome inhibitors for the treatment of multiple myeloma.
  Jehanzeb Riaz, Rashmi Verma, Leonardo Mirandola, Jose A. Figueroa, et al, J Clin Oncol, 1/1/2014
• Effect of the Novel Galectin-3 Blocker, Gal3M, on the Efficacy and Reduction of Toxicity of Proteasome Inhibitors for the Treatment of Multiple Myeloma
  Jehanzeb Riaz, Rashmi Verma, Leonardo Mirandola, Jose A. Figueroa, et al., J Clin Oncol, 1/1/2014
• Cancer Testes Antigens: Potential New targets for Lung Cancer
  Leonardo Mirandola, Jehanzeb Riaz, Rashmi Verma, Saba Radhi, Teresia Pham, Amardeep Aulakh, Venu Konala, Yuefei Yu, Fred Hardwick, Lukman Aderoju Tijani, Nicholas C. D..., J Clin Oncol, 1/1/2014
• Effect of Galectin-3 Inhibition on Drug Resistance, Motility, Invasion, and Angiogenic Potential in Ovarian Cancer.
  Rashmi Verma, Jehanzeb Riaz, Leonardo Mirandola, Jose A. Figueroa, et al., J Clin Oncol, 1/1/2014
• Chemokine Receptors as Novel Targets of the Oncogene Notch1 in Acute Lymphoblastic Leukemia
  Leonardo Mirandola, Maurizio Chiriva-Internati, Everardo Cobos, Yuefei Yu, Jose A. Figueroa, Silvia Garavelli, Michela Colombo, Elisa Lazzari, Natalia Platonova, Krist..., J Clin Oncol, 1/1/2013
• Cancer/testis antigens for immunotherapy and detection of multiple myeloma.
  Chiriva-Internati M, Kim E, Figueroa A, Littlefield L, Saadeh C, Wade R, Giridhar V, Mer J, Mirandola L, Yu Y, Hardwicke F, D'Cunha N, Tijani L, Nguyen D, Figueroa JA,..., AACR Annual Meeting, Texas Tech University Health Sciences Center, Lubbock, TX, 1/1/2013
• Combination of SP17 with CA125 serologic measurement for detection of ovarian cancer.
  Chiriva-Internati M, Mirandola, L, Yu Y, Jenkins MR, Cobos E, Figueroa JA, Nijman H, Kast M, AACR Frontiers in Cancer Prevention, 1/1/2013
• Chemokine receptors as novel targets of the oncogene Notch1 in acute lymphoblastic leukemia.
  Leonardo Mirandola, Maurizio Chiriva-Internati, Everardo Cobos, Yuefei Yu, Jose A. Figueroa, Silvia Garavelli, Michela Colombo, Elisa Lazzari, Natalia Platonova, Krist..., J Clin Oncol, 1/1/2013
• Promotion of human multiple myeloma cell growth in vitro and bone marrow invasion in vivo by Notch receptors and the CXCR4/SDF1 axis.
  Maurizio Chiriva-Internati, Leonardo Mirandola, Elisa Lazzari, Michela Colombo, Marialuigia Lancellotti, Everardo Cobos, Yuefei Yu, Jose A. Figueroa, Charles Saadeh, R..., J Clin Oncol, 1/1/2013
• The impact of sex on ropporin expression in multiple myeloma patients.
  Raymond Wade, Saba Radhi, Maurizio Chiriva-Internati, Fred Hardwick, Jesse Mer, Amardeep Aulakh, Charles Saadeh, Yuefei Yu, Leonardo Mirandola, Kristopher Zepeda, Raff..., J Clin Oncol, 1/1/2013
• Selective expression of the Sp17/AKAP4/PTTG1 in NSCLC for detection and therapy.
  Saba Radhi, Charles Saadeh, Raymond Wade, Jesse Mer, Yuefei Yu, Leonardo Mirandola, Venu Konala, Amardeep Aulakh, Raffaella Chiaramonte, Natalia Platonova, Kristopher ..., J Clin Oncol, 1/1/2013
• Selective Expression of the Sp17/AKAP4/PTTG1 in NSCLC for Detection and Therapy
  Saba Radhi, Charles Saadeh, Raymond Wade, Jesse Mer, Yuefei Yu, Leonardo Mirandola, Venu Konala, Amardeep Aulakh, Raffaella Chiaramonte, Natalia Platonova, Kristopher ..., J Clin Oncol, 1/1/2013
• Promotion of Human Multiple Myeloma Cell Growth in Vitro and Bone Marrow Invasion in Vivo by Notch Receptors and the CXCR4/SDF1 Axis
  Maurizio Chiriva-Internati, Leonardo Mirandola, Elisa Lazzari, Michela Colombo, Marialuigia Lancellotti, Everardo Cobos, Yuefei Yu, Jose A. Figueroa, Charles Saadeh, R..., J Clin Oncol, 1/1/2013
• Relationship of the Oncogene Notch and CXCR4/SDF1 Signaling in Human Epithelial Ovarian Cancer
  Venu Konala, Natalia Platonova, Michela Colombo, Leonardo Mirandola, Elisa Lazzari, Daria De Simone, Saba Radhi, Amardeep Aulakh, Kristopher Zepeda, Raymond Wade, Jess..., J Clin Oncol, 1/1/2013
• The Impact of Sex on Ropporin Expression in Multiple Myeloma Patients
  Raymond Wade, Saba Radhi, Maurizio Chiriva-Internati, Fred Hardwick, Jesse Mer, Amardeep Aulakh, Charles Saadeh, Yuefei Yu, Leonardo Mirandola, Kristopher Zepeda, Raff..., J Clin Oncol, 1/1/2013
• Texas Tech University Health Sciences Center, Lubbock, TX. Cancer/testis Antigens for Immunotherapy and Detection of Multiple Myeloma
  Chiriva-Internati M, Kim E, Figueroa A, Littlefield L, Saadeh C, Wade R, Giridhar V, Mer J, Mirandola L, Yu Y, Hardwicke F, D'Cunha N, Tijani L, Nguyen D, Figueroa JA,..., AACR Annual Meeting, 1/1/2013
• Relationship of the oncogene Notch and CXCR4/SDF1 signaling in human epithelial ovarian cancer.
  Venu Konala, Natalia Platonova, Michela Colombo, Leonardo Mirandola, Elisa Lazzari, Daria De Simone, Saba Radhi, Amardeep Aulakh, Kristopher Zepeda, Raymond Wade, Jess..., J Clin Oncol, 1/1/2013
• Effect of enzastaurin in patients with colorectal cancer treated with irinotecan plus cetuximab.
  Iqbal S, Miller C, Figueroa J, Hossain A, Nicol S, Mulcathy M, 12th World Congress on Gastrointestinal Cancer, 1/30/2010
• Phase I pharmacokinetic, dose-escalation study of EZN-2968, a novel hypoxia-inducible factor-1 alpha (HIFa) messenger ribonucleic acid (mRNA) antagonist in patients wi...
  L.P. Martin, R. Cohen, R.J. Schilder, H. Hurwitz, G. Vlahovic, J.A. Figueroa, and A. Buchbinder, Proc ASCO, 1/1/2010
• Phase II study Multicenter Trial of Genexol-PM, a Novel Cremophor-Free Polymeric Micell Formulation of Paclitaxel in Patients with Advanced Pancreatic Cancer (APC).
  M.W. Saif, M.S. Rubin, J.A. Figueroa, R.O. Kerr, ASCO Gastrointestinal Cancer Symposium, 1/1/2008
• Phase II Clinical trial of Paclitaxel loaded polymeric micelle (GPM) in patients with advanced pancreatic cancer (APC). Final Results.
  N.A. Podoltsev, M.S. Rubin, J.A. Figueroa, et al, J Clin Oncol, 1/1/2008
• Phase I pharmacokinetic, dose-escalation study of ENZ2968, a novel hypoxia-inducible factor-1 alpha (HIFa) antagonist administered weekly in patients with solid tumors.
  N. Lewis, R. Cohen, Y. Nishida, H. Hurwitz, C. Arrowwood, H. Uronis, F. Gamza, A. Buchbinder and J. Figueroa, Proc AACR-NCI-EORTC International Conference, 1/1/2008
• Join now to see all

Lectures

• SP17 as a New Immunotherapy Target and Biomarker for Triple Negative Breast Cancer 
  1/1/2015
• Translational Research Conference: Cell Cycle Regulation 
  1/1/2014
• Clinical Research Conference (Monthly) 
  1/1/2014
• Design of Phase I Clinical Trials 
  1/1/2014
• Design of Phase II Clinical Trials 
  1/1/2014
• Fundamentals of Statistical Analysis 
  1/1/2014
• Journal Club Discussion: Checkpoint inhibition in melanoma 
  1/1/2014
• Primary Bone Malignancies 
  1/1/2014
• Pulmonary Small Cell Lung Carcinomas 
  1/1/2014
• Special Situations in Breast Cancer 
  1/1/2014
• Thymomas and Thymic Carcinomas 
  1/1/2014
• Combination of SP17 with CA125 Serologic Measurement for Detection of Ovarian Cancer 
  1/1/2013
• Phase I Pharmacokinetic, Dose-escalation Study of EZN-2968, a Novel Hypoxia-inducible Factor-1 Alpha (HIFa) Messenger Ribonucleic Acid (MRNA) Antagonist in Patients wi... 
  1/1/2010
• Phase I Pharmacokinetic, Dose-escalation Study of ENZ2968, a Novel Hypoxia-inducible Factor-1 Alpha (HIFa) Antagonist Administered Weekly in Patients with Solid Tumors 
  1/1/2008
• Phase II study Multicenter Trial of Genexol(R)-PM, a Novel Cremophor-Free Polymeric Micell Formulation of Paclitaxel in Patients with Advanced Pancreatic Cancer (APC). 
  1/1/2008
• Phase II Study of a Novel Micellar Paclitaxel Formulation for Treatment of Pancreatic Cancer 
  1/1/2007
• Final Results of a Phase I Study Using Oral Temozolomide Daily for 14 Days with Weekly Paclitaxel in Patients with Advanced Malignancies 
  1/1/2006
• A Phase II Study of Induction Therapy with Gemcitabine + Carboplatin Followed by Either Delayed vs Immediate Second Line Therapy with Docetaxel in Advanced Non-small C... 
  1/1/2005
• Dose-finding Study of Oral Temozolomide Administered for 14 Days together with Weekly, Fixed-dose Paclitaxel in Patients with Advanced Malignancies 
  1/1/2003
• Advances in the Treatment of Malignant Melanoma. 
  1/1/2003
• Advances in the Treatment of Malignant Melanoma 
  1/1/2003
• Phase I/II Trial of ISIS 3521 Antisense Inhibitor PKC-alpha with Cisplatin and Gemcitabine in Advanced Non-small Cell Lung Cancer 
  1/1/2002
• Phase II Evaluation of OSI-774, a Potent Oral Antagonist of the EGFR-TK in Patients with Advanced Ovarian Cancer 
  1/1/2001
• Phase I and Pharmacokinetic Study of the Protein Kinase C Alpha Inhibitor ISIS 3521 in Combination with Cisplatin and Gemcitabine in Patients with Solid Malignancies 
  1/1/2001
• Expression of Insulin-like Receptor-1 and IGF Binding Proteins-2 1nd-3 in Primary Tumors and Nodal Metastases from Stage III NSCLC 
  1/1/2001
• Join now to see all